Korean J Hematol.  2011 Sep;46(3):145-147. 10.5045/kjh.2011.46.3.145.

Low-grade lymphoma: Beyond fludarabine-single therapy

• Park E

• KMID: 2251993
• DOI: http://doi.org/10.5045/kjh.2011.46.3.145

Abstract

No abstract available.

Reference

1. Horning SJ. Natural history of and therapy for the indolent non-Hodgkin's lymphomas. Semin Oncol. 1993; 20(5 Suppl 5):75–88. PMID: 8211209.

2. McLaughlin P, Hagemeister FB, Romaguera JE, et al. Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma. J Clin Oncol. 1996; 14:1262–1268. PMID: 8648382.

3. Zinzani PL, Bendandi M, Magagnoli M, Gherlinzoni F, Merla E, Tura S. Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade non-Hodgkin's lymphoma. Ann Oncol. 1997; 8:379–383. PMID: 9209669.

4. Lazzarino M, Orlandi E, Montillo M, et al. Fludarabine, cyclophosphamide, and dexamethasone (FluCyD) combination is effective in pretreated low-grade non-Hodgkin's lymphoma. Ann Oncol. 1999; 10:59–64. PMID: 10076723.

5. Zinzani PL, Magagnoli M, Bendandi M, et al. Efficacy of fludarabine and mitoxantrone (FN) combination regimen in untreated indolent non-Hodgkin's lymphomas. Ann Oncol. 2000; 11:363–365. PMID: 10811507.

6. Ferrario A, Merli F, Luminari S, et al. Phase II fludarabine and cyclophosphamide for the treatment of indolent B cell non-follicular lymphomas: final results of the LL02 trial of the Gruppo Italiano per lo Studio dei Linfomi (GISL). Ann Hematol. 2011; 90:323–330. PMID: 20848104.

7. Eichhorst BF, Busch R, Hopfinger G, et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood. 2006; 107:885–891. PMID: 16219797.

8. van Oers MH, Klasa R, Marcus RE, et al. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial. Blood. 2006; 108:3295–3301. PMID: 16873669.

9. Dreyling M, Forstpointner R, Gramatzki M, et al. Rituximab maintenance improves progression-free and overall survival rates after combined immuno-chemotherapy (R-FCM) in patients with relapsed follicular and mantle cell lymphoma: final results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol. 2006; 24(Suppl 18):7502.

10. Fowler N, Kahl BS, Lee P, et al. Bortezomib, bendamustine, and rituximab in patients with relapsed or refractory follicular lymphoma: the phase II VERTICAL study. J Clin Oncol. 2011; 29:3389–3395. PMID: 21810687.